3.Evaluation and treatment of sepsis-induced myocardial dysfunction: a systematic study.
Chinese Critical Care Medicine 2019;31(3):378-380
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. The early mortality of patients with sepsis-induced myocardial dysfunction (SMD) is higher than those with normal cardiac function, and the long-term prognosis is worse. Therefore, early detection of SMD and timely intervention can reduce mortality and improve prognosis. This review focused on the progress in evaluation and treatment of SMD, with a view to provide some ideas for the diagnosis and treatment of SMD.
Cardiomyopathies/therapy*
;
Humans
;
Sepsis/complications*
8.Eosinophilic cardiomyopathy in a child.
Zhi-Hong ZHUO ; Huai-Li WANG ; Qiang LUO ; Qian ZHANG ; Tie-Zheng GAO
Chinese Journal of Contemporary Pediatrics 2009;11(10):858-859
Cardiomyopathies
;
diagnosis
;
therapy
;
Child
;
Eosinophilia
;
diagnosis
;
therapy
;
Humans
;
Male
9.Cirrhotic Cardiomyopathy.
Moon Young KIM ; Soon Koo BAIK
The Korean Journal of Hepatology 2007;13(1):20-26
Most patients with liver cirrhosis have hyperdynamic circulatory alterations with increased cardiac output, and decreased systemic vascular resistance and arterial pressure. But, in spite of the increased resting cardiac output, ventricular contractile response to stressful stimuli is attenuated in cirrhotic patients which is termed as cirrhotic cardiomyopathy. The prevalence of cirrhotic cardiomyopathy remains unknown at present. Clinical features include structural, histological, electrophysiological, systolic and diastolic dysfunction. Multiple factors are considered as responsible, including impaired beta-adrenergic receptor signal transduction, abnormal membrane biophysical characteristics, and increased activity of cardiodepressant systems mediated by cGMP. Generally, cirrhotic cardiomyopathy with overt severe heart failure is rare. However, major stresses on the cardiovascular system such as liver transplantation, infections and insertion of transjugular intrahepatic portosystemic shunts (TIPS) can unmask the presence of cirrhotic cardiomyopathy and thereby convert latent to overt heart failure. Cirrhotic cardiomyopathy may also contribute to the pathogenesis of hepatorenal syndrome and circulatory failure in liver cirrhosis. Because of the marked paucity of treatment studies, current recommendations for management are empirical, nonspecific measures. Further studies for pathogenesis and new therapeutic strategies in this area are required.
Cardiomyopathies/*diagnosis/*etiology/therapy
;
Humans
;
Liver Cirrhosis/*complications
;
Prognosis
Result Analysis
Print
Save
E-mail